Keywords
Last Name
Institution

Marshall Posner

TitlePROFESSOR
InstitutionMount Sinai
DepartmentHematology and Medical Oncology
Address1470 Madison Avenue
3rd floor
New York NY 10029
Phone212-241-6756
Fax212-241-7141
    Other Positions
    TitlePROFESSOR
    InstitutionMount Sinai
    DepartmentOtolaryngology


     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Misiukiewicz K, Posner M. The SPECTRUM of findings in treatment options for recurrent/metastatic head and neck cancer. J Comp Eff Res. 2013 Nov; 2(6):533-5.
      View in: PubMed
    2. Kostakoglu L, Fardanesh R, Posner M, Som P, Rao S, Park E, Doucette J, Stein EG, Gupta V, Misiukiewicz K, Genden E. Early detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck. Oncologist. 2013; 18(10):1108-17.
      View in: PubMed
    3. Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Hernandez JJ, Bourredjem A, Calais G, Paccagnella A, Hitt R, Pignon JP. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol. 2013 Aug 10; 31(23):2854-60.
      View in: PubMed
    4. Limaye S, Riley S, Zhao S, O'Neill A, Posner M, Adkins D, Jaffa Z, Clark J, Haddad R. A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). Oral Oncol. 2013 Aug; 49(8):835-41.
      View in: PubMed
    5. Misiukiewicz KJ, Camille N, Tishler R, Haddad R, Limaye S, Posner M. Organ preservation for adenoid cystic carcinoma of the larynx. Oncologist. 2013; 18(5):579-83.
      View in: PubMed
    6. Fogg M, Murphy JR, Lorch J, Posner M, Wang F. Therapeutic targeting of regulatory T cells enhances tumor-specific CD8+ T cell responses in Epstein-Barr virus associated nasopharyngeal carcinoma. Virology. 2013 Jul 5; 441(2):107-13.
      View in: PubMed
    7. Limaye SA, Posner MR, Krane JF, Fonfria M, Lorch JH, Dillon DA, Shreenivas AV, Tishler RB, Haddad RI. Trastuzumab for the treatment of salivary duct carcinoma. Oncologist. 2013; 18(3):294-300.
      View in: PubMed
    8. Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013 Mar; 14(3):257-64.
      View in: PubMed
    9. Chu A, Genden E, Posner M, Sikora A. A patient-centered approach to counseling patients with head and neck cancer undergoing human papillomavirus testing: a clinician's guide. Oncologist. 2013; 18(2):180-9.
      View in: PubMed
    10. Genden EM, Sambur IM, de Almeida JR, Posner M, Rinaldo A, Rodrigo JP, Strojan P, Takes RP, Ferlito A. Human papillomavirus and oropharyngeal squamous cell carcinoma: what the clinician should know. Eur Arch Otorhinolaryngol. 2013 Feb; 270(2):405-16.
      View in: PubMed
    11. Posner M. Clinical trials in squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol. 2012 Jun; 10(6):388-90.
      View in: PubMed
    12. Bonomi MR, Misiukiewicz K, Posner M, Maki RG. Squamous cell carcinoma of the oral tongue in two patients previously exposed to long-term pegylated liposomal doxorubicin. Oncologist. 2012; 17(12):1594-5.
      View in: PubMed
    13. Misiukiewicz K, Posner M. Time to change the treatment paradigms in anaplastic thyroid carcinoma. Oncology (Williston Park). 2012 Apr; 26(4):408, 410.
      View in: PubMed
    14. Sher DJ, Thotakura V, Balboni TA, Norris CM, Haddad RI, Posner MR, Lorch J, Goguen LA, Annino DJ, Tishler RB. Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. Ann Oncol. 2012 Sep; 23(9):2391-8.
      View in: PubMed
    15. Lu W, Wayne PM, Davis RB, Buring JE, Li H, Goguen LA, Rosenthal DS, Tishler RB, Posner MR, Haddad RI. Acupuncture for dysphagia after chemoradiation in head and neck cancer: rationale and design of a randomized, sham-controlled trial. Contemp Clin Trials. 2012 Jul; 33(4):700-11.
      View in: PubMed
    16. Wu Y, Posner MR, Schumaker LM, Nikitakis N, Goloubeva O, Tan M, Lu C, Iqbal S, Lorch J, Sarlis NJ, Haddad RI, Cullen KJ. Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer: an analysis of the TAX 324 trial. Cancer. 2012 Apr 1; 118(7):1811-7.
      View in: PubMed
    17. Anderson KS, Wong J, D'Souza G, Riemer AB, Lorch J, Haddad R, Pai SI, Longtine J, McClean M, LaBaer J, Kelsey KT, Posner M. Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br J Cancer. 2011 Jun 7; 104(12):1896-905.
      View in: PubMed
    18. Sher DJ, Thotakura V, Balboni TA, Norris CM, Haddad RI, Posner MR, Lorch J, Goguen LA, Annino DJ, Tishler RB. Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e215-22.
      View in: PubMed
    19. Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, Haddad RI, Cullen KJ. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol. 2011 May; 22(5):1071-7.
      View in: PubMed
    20. Sher DJ, Posner MR, Tishler RB, Sarlis NJ, Haddad RI, Holupka EJ, Devlin PM. Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. Int J Radiat Oncol Biol Phys. 2011 Dec 1; 81(5):e813-8.
      View in: PubMed
    21. Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011 Feb; 12(2):153-9.
      View in: PubMed
    22. Cooley ME, Emmons KM, Haddad R, Wang Q, Posner M, Bueno R, Cohen TJ, Johnson BE. Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer. Cancer. 2011 Jul 1; 117(13):2961-9.
      View in: PubMed
    23. Sher DJ, Balboni TA, Haddad RI, Norris CM, Posner MR, Wirth LJ, Goguen LA, Annino D, Tishler RB. Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys. 2011 Aug 1; 80(5):1405-11.
      View in: PubMed
    24. Schoenfeld JD, Sher DJ, Norris CM, Haddad RI, Posner MR, Balboni TA, Tishler RB. Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys. 2012 Jan 1; 82(1):308-14.
      View in: PubMed
    25. Prince A, Aguirre-Ghizo J, Genden E, Posner M, Sikora A. Head and neck squamous cell carcinoma: new translational therapies. Mt Sinai J Med. 2010 Nov-Dec; 77(6):684-99.
      View in: PubMed
    26. Sher DJ, Haddad RI, Norris CM, Posner MR, Wirth LJ, Goguen LA, Annino D, Balboni T, Allen A, Tishler RB. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer. 2010 Oct 15; 116(20):4761-8.
      View in: PubMed
    27. Posner MR. Integrating systemic agents into multimodality treatment of locally advanced head and neck cancer. Ann Oncol. 2010 Oct; 21 Suppl 7:vii246-51.
      View in: PubMed
    28. Lu W, Posner MR, Wayne P, Rosenthal DS, Haddad RI. Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: a case series report. Integr Cancer Ther. 2010 Sep; 9(3):284-90.
      View in: PubMed
    29. Agoston ES, Robinson SJ, Mehra KK, Birch C, Semmel D, Mirkovic J, Haddad RI, Posner MR, Kindelberger D, Krane JF, Brodsky J, Crum CP. Polymerase chain reaction detection of HPV in squamous carcinoma of the oropharynx. Am J Clin Pathol. 2010 Jul; 134(1):36-41.
      View in: PubMed
    30. Poage GM, Christensen BC, Houseman EA, McClean MD, Wiencke JK, Posner MR, Clark JR, Nelson HH, Marsit CJ, Kelsey KT. Genetic and epigenetic somatic alterations in head and neck squamous cell carcinomas are globally coordinated but not locally targeted. PLoS One. 2010; 5(3):e9651.
      View in: PubMed
    31. Goguen LA, Norris CM, Jaklitsch MT, Sullivan CA, Posner MR, Haddad RI, Tishler RB, Burke E, Annino DJ. Combined antegrade and retrograde esophageal dilation for head and neck cancer-related complete esophageal stenosis. Laryngoscope. 2010 Feb; 120(2):261-6.
      View in: PubMed
    32. Cullen KJ, Schumaker L, Nikitakis N, Goloubeva O, Tan M, Sarlis NJ, Haddad RI, Posner MR. beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial. J Clin Oncol. 2009 Dec 20; 27(36):6222-8.
      View in: PubMed
    33. Wirth LJ, Allen AM, Posner MR, Haddad RI, Li Y, Clark JR, Busse PM, Chan AW, Goguen LA, Norris CM, Annino DJ, Tishler RB. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol. 2010 Feb; 21(2):342-7.
      View in: PubMed
    34. Parthan A, Posner MR, Brammer C, Beltran P, Jansen JP. Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck. Head Neck. 2009 Oct; 31(10):1255-62.
      View in: PubMed
    35. Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P, Allen A, Mahadevan A, Flynn J, Burke E, Li Y, Tishler RB. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer. 2009 Oct 1; 115(19):4514-23.
      View in: PubMed
    36. Haddad RI, Tishler RB, Norris C, Goguen L, Balboni TA, Costello R, Wirth L, Lorch J, Andreozzi B, Annino D, Posner MR. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2009 Sep 20; 27(27):4448-53.
      View in: PubMed
    37. Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, Strome SE, Haddad RI, Patel SS, Cambell EV, Sarlis N, Lorch J, Cullen KJ. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila). 2009 Sep; 2(9):776-81.
      View in: PubMed
    38. Haddad RI, Posner MR. Induction chemotherapy in head and neck cancer. J Clin Oncol. 2009 Aug 10; 27(23):e52-3; author reply e54.
      View in: PubMed
    39. Chen AA, Marsit CJ, Christensen BC, Houseman EA, McClean MD, Smith JF, Bryan JT, Posner MR, Nelson HH, Kelsey KT. Genetic variation in the vitamin C transporter, SLC23A2, modifies the risk of HPV16-associated head and neck cancer. Carcinogenesis. 2009 Jun; 30(6):977-81.
      View in: PubMed
    40. Boshoff C, Posner M. Targeting EGFR in head and neck cancer: a decade of progress. Nat Clin Pract Oncol. 2009 Mar; 6(3):123.
      View in: PubMed
    41. Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, Winquist EW, Blajman CR, Mickiewicz EA, Frenette GP, Plinar LF, Cohen RB, Steinbrenner LM, Freue JM, Gorbunova VA, Tjulandin SA, Raez LE, Adkins DR, Tishler RB, Roessner MR, Haddad RI. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol. 2009 May; 20(5):921-7.
      View in: PubMed
    42. Marsit CJ, Christensen BC, Houseman EA, Karagas MR, Wrensch MR, Yeh RF, Nelson HH, Wiemels JL, Zheng S, Posner MR, McClean MD, Wiencke JK, Kelsey KT. Epigenetic profiling reveals etiologically distinct patterns of DNA methylation in head and neck squamous cell carcinoma. Carcinogenesis. 2009 Mar; 30(3):416-22.
      View in: PubMed
    43. Furniss CS, McClean MD, Smith JF, Bryan J, Applebaum KM, Nelson HH, Posner MR, Kelsey KT. Human papillomavirus 6 seropositivity is associated with risk of head and neck squamous cell carcinoma, independent of tobacco and alcohol use. Ann Oncol. 2009 Mar; 20(3):534-41.
      View in: PubMed
    44. Lorch JH, Posner MR, Wirth LJ, Haddad RI. Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? Hematol Oncol Clin North Am. 2008 Dec; 22(6):1155-63, viii.
      View in: PubMed
    45. Lorch JH, Posner MR, Wirth LJ, Haddad RI. Seeking alternative biological therapies: the future of targeted molecular treatment. Oral Oncol. 2009 Apr-May; 45(4-5):447-53.
      View in: PubMed
    46. Wirth LJ, Krane JF, Li Y, Othus M, Moran AE, Dorfman DM, Norris CM, Goguen L, Posner MR, Haddad RI, Bertagnolli MM. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila). 2008 Oct; 1(5):339-48.
      View in: PubMed
    47. Marsit CJ, Posner MR, McClean MD, Kelsey KT. Hypermethylation of E-cadherin is an independent predictor of improved survival in head and neck squamous cell carcinoma. Cancer. 2008 Oct 1; 113(7):1566-71.
      View in: PubMed
    48. Russo G, Haddad R, Posner M, Machtay M. Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist. 2008 Aug; 13(8):886-98.
      View in: PubMed
    49. Posner M, Vermorken JB. Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. Semin Oncol. 2008 Jun; 35(3):221-8.
      View in: PubMed
    50. Caglar HB, Tishler RB, Othus M, Burke E, Li Y, Goguen L, Wirth LJ, Haddad RI, Norris CM, Court LE, Aninno DJ, Posner MR, Allen AM. Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):1110-8.
      View in: PubMed
    51. Marsit CJ, Black CC, Posner MR, Kelsey KT. A genotype-phenotype examination of cyclin D1 on risk and outcome of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2008 Apr 15; 14(8):2371-7.
      View in: PubMed
    52. Haddad R, Crum C, Chen Z, Krane J, Posner M, Li Y, Burk R. HPV16 transmission between a couple with HPV-related head and neck cancer. Oral Oncol. 2008 Aug; 44(8):812-5.
      View in: PubMed
    53. Applebaum KM, Furniss CS, Zeka A, Posner MR, Smith JF, Bryan J, Eisen EA, Peters ES, McClean MD, Kelsey KT. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst. 2007 Dec 5; 99(23):1801-10.
      View in: PubMed
    54. Wirth LJ, Posner MR. Recent advances in combined modality therapy for locally advanced head and neck cancer. Curr Cancer Drug Targets. 2007 Nov; 7(7):674-80.
      View in: PubMed
    55. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM, Haddad RI. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007 Oct 25; 357(17):1705-15.
      View in: PubMed
    56. Posner MR, Haddad RI. Novel agents for the treatment of mucositis. J Support Oncol. 2007 Oct; 5(9 Suppl 4):33-9.
      View in: PubMed
    57. Posner M. Evolving strategies for combined-modality therapy for locally advanced head and neck cancer. Oncologist. 2007 Aug; 12(8):967-74.
      View in: PubMed
    58. Furniss CS, McClean MD, Smith JF, Bryan J, Nelson HH, Peters ES, Posner MR, Clark JR, Eisen EA, Kelsey KT. Human papillomavirus 16 and head and neck squamous cell carcinoma. Int J Cancer. 2007 Jun 1; 120(11):2386-92.
      View in: PubMed
    59. Chambers MS, Posner M, Jones CU, Biel MA, Hodge KM, Vitti R, Armstrong I, Yen C, Weber RS. Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1102-9.
      View in: PubMed
    60. Haddad R, Wirth L, Posner M. Emerging drugs for head and neck cancer. Expert Opin Emerg Drugs. 2006 Sep; 11(3):461-7.
      View in: PubMed
    61. Sonis S, Haddad R, Posner M, Watkins B, Fey E, Morgan TV, Mookanamparambil L, Ramoni M. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol. 2007 Mar; 43(3):289-300.
      View in: PubMed
    62. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006 Aug 1; 24(22):3693-704.
      View in: PubMed
    63. Goguen LA, Posner MR, Norris CM, Tishler RB, Wirth LJ, Annino DJ, Gagne A, Sullivan CA, Sammartino DE, Haddad RI. Dysphagia after sequential chemoradiation therapy for advanced head and neck cancer. Otolaryngol Head Neck Surg. 2006 Jun; 134(6):916-22.
      View in: PubMed
    64. Haddad R, Tishler R, Wirth L, Norris CM, Goguen L, Sullivan C, O'Donnell L, Li Y, Posner M. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2006 Jun; 132(6):678-81.
      View in: PubMed
    65. Tishler RB, Posner MR, Norris CM, Mahadevan A, Sullivan C, Goguen L, Wirth LJ, Costello R, Case M, Stowell S, Sammartino D, Busse PM, Haddad RI. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1036-44.
      View in: PubMed
    66. Goguen LA, Posner MR, Tishler RB, Wirth LJ, Norris CM, Annino DJ, Sullivan CA, Li Y, Haddad RI. Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006 May; 132(5):526-31.
      View in: PubMed
    67. Haddad RI, Posner MR, Busse PM, Norris CM, Goguen LA, Wirth LJ, Blinder R, Krane JF, Tishler RB. Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Am J Clin Oncol. 2006 Apr; 29(2):153-7.
      View in: PubMed
    68. Posner MR, Wirth LJ. Cetuximab and radiotherapy for head and neck cancer. N Engl J Med. 2006 Feb 9; 354(6):634-6.
      View in: PubMed
    69. Haddad R, Allen A, Wirth L, Tishler R, Posner M. Integrating novel agents into the curative treatment of head and neck cancer. Expert Rev Anticancer Ther. 2006 Feb; 6(2):157-9.
      View in: PubMed
    70. Amrein PC, Clark JR, Supko JG, Fabian RL, Wang CC, Colevas AD, Posner MR, Deschler DG, Rocco JW, Finkelstein DM, McIntyre JF. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. Cancer. 2005 Oct 1; 104(7):1418-27.
      View in: PubMed
    71. Wirth LJ, Haddad RI, Lindeman NI, Zhao X, Lee JC, Joshi VA, Norris CM, Posner MR. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2005 Oct 1; 23(28):6976-81.
      View in: PubMed
    72. Guadagnolo BA, Haddad RI, Posner MR, Weeks L, Wirth LJ, Norris CM, Sullivan CA, Goguen L, Busse PM, Tishler R. Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Am J Clin Oncol. 2005 Aug; 28(4):371-8.
      View in: PubMed
    73. Mager DL, Haffajee AD, Devlin PM, Norris CM, Posner MR, Goodson JM. The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects. J Transl Med. 2005; 3:27.
      View in: PubMed
    74. Cao W, Cavacini LA, Tillman KC, Posner MR. CD40 function in squamous cell cancer of the head and neck. Oral Oncol. 2005 May; 41(5):462-9.
      View in: PubMed
    75. Posner MR. Adjuvant post-operative chemoradiotherapy in head and neck cancer: a standard of care? Oncologist. 2005 Mar; 10(3):174-5.
      View in: PubMed
    76. Haddad R, Mahadevan A, Posner MR, Sullivan C. Long term survival with adjuvant carboplatin, paclitaxel, and radiation therapy in anaplastic thyroid cancer. Am J Clin Oncol. 2005 Feb; 28(1):104.
      View in: PubMed
    77. Posner MR. Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy. Oncologist. 2005; 10 Suppl 3:11-9.
      View in: PubMed
    78. Gokhale AS, Haddad RI, Cavacini LA, Wirth L, Weeks L, Hallar M, Faucher J, Posner MR. Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncol. 2005 Jan; 41(1):70-6.
      View in: PubMed
    79. Posner MR, Haddad RI, Wirth L, Norris CM, Goguen LA, Mahadevan A, Sullivan C, Tishler RB. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol. 2004 Dec; 31(6):778-85.
      View in: PubMed
    80. Sullivan CA, Jaklitsch MT, Haddad R, Goguen LA, Gagne A, Wirth LJ, Posner MR, Tishler RB, Norris CM. Endoscopic management of hypopharyngeal stenosis after organ sparing therapy for head and neck cancer. Laryngoscope. 2004 Nov; 114(11):1924-31.
      View in: PubMed
    81. McCollum AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, Posner MR, Van den Abbeele AD. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004 Oct; 26(10):890-6.
      View in: PubMed
    82. Fisher RA, Maluf D, Cotterell AH, Stravitz T, Wolfe L, Luketic V, Sterling R, Shiffman M, Posner M. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant. 2004 Oct; 18(5):502-12.
      View in: PubMed
    83. Devlin PM, Kazakin J, Adak S, Li Y, Norris CM, Tishler RB, Clark JR, Busse PM, Posner MR. Prospective phase II trial of PFL-induction chemotherapy followed by definitive local treatment for advanced squamous cell carcinoma of the head and neck: 10-year follow-up. Am J Clin Oncol. 2004 Aug; 27(4):369-75.
      View in: PubMed
    84. Haddad RI, Weinstein LJ, Wieczorek TJ, Bhattacharya N, Raftopoulos H, Oster MW, Zhang X, Latham VM, Costello R, Faucher J, DeRosa C, Yule M, Miller LP, Loda M, Posner MR, Shapiro GI. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin Cancer Res. 2004 Jul 15; 10(14):4680-7.
      View in: PubMed
    85. Pignon JP, Syz N, Posner M, Olivares R, Le Lann L, Yver A, Dunant A, Lewin F, Dalley DN, Paccagnella A, Taylor SG, Domenge C, Bourhis J, Mazumdar M. Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. Anticancer Drugs. 2004 Apr; 15(4):331-40.
      View in: PubMed
    86. Kotz T, Costello R, Li Y, Posner MR. Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck. Head Neck. 2004 Apr; 26(4):365-72.
      View in: PubMed
    87. Haddad RI, Tishler RB, Posner MR. Nonsurgical treatment of laryngeal cancer. N Engl J Med. 2004 Mar 4; 350(10):1049-53; author reply 1049-53.
      View in: PubMed
    88. Glisson B, Colevas AD, Haddad R, Krane J, El-Naggar A, Kies M, Costello R, Summey C, Arquette M, Langer C, Amrein PC, Posner M. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004 Feb 1; 10(3):944-6.
      View in: PubMed
    89. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene. 2004 Jan 29; 23(4):1000-4.
      View in: PubMed
    90. Haddad R, Posner M. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet. 2004 Jan 3; 363(9402):79-80; author reply 81-2.
      View in: PubMed
    91. Haddad R, Wirth L, Costello R, Weeks L, Posner M. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Semin Oncol. 2003 Dec; 30(6 Suppl 18):84-8.
      View in: PubMed
    92. Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, Weeks L, Costello R, Posner M. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003 Oct; 39(7):724-7.
      View in: PubMed
    93. Haddad RI, Wirth L, Posner MR. Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer. Expert Rev Anticancer Ther. 2003 Jun; 3(3):331-8.
      View in: PubMed
    94. Wirth LJ, Haddad RI, Posner MR. Progress and perspectives in chemoprevention of head and neck cancer. Expert Rev Anticancer Ther. 2003 Jun; 3(3):339-55.
      View in: PubMed
    95. Haddad R, Posner MR. Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine. Clin Adv Hematol Oncol. 2003 Apr; 1(4):226-8.
      View in: PubMed
    96. Haddad R, Posner M. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2003 Mar 15; 97(6):1589; author reply 1590.
      View in: PubMed
    97. Maluf D, Fisher RA, Maroney T, Cotterell A, Fulcher A, Tisnado J, Contos M, Luketic V, Stravitz R, Shiffman M, Sterling R, Posner M. Non-resective ablation and liver transplantation in patients with cirrhosis and hepatocellular carcinoma (HCC): safety and efficacy. Am J Transplant. 2003 Mar; 3(3):312-7.
      View in: PubMed
    98. Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C, Norris CM, Lake-Willcutt B, Case MA, Costello R, Posner M. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer. 2003 Jan 15; 97(2):412-8.
      View in: PubMed
    99. Posner MR, Lefebvre JL. Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. Br J Cancer. 2003 Jan 13; 88(1):11-7.
      View in: PubMed
    100. Haddad R, Tishler RB, Norris CM, Mahadevan A, Busse P, Wirth L, Goguen LA, Sullivan CA, Costello R, Case MA, Posner MR. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist. 2003; 8(1):35-44.
      View in: PubMed
    101. Haddad R, Norris CM, Posner MR. A 49-year-old male with locally advanced squamous cell carcinoma of the head and neck: the case for sequential chemoradiotherapy. Clin Adv Hematol Oncol. 2003 Jan; 1(1):58-60; discussion 61-2.
      View in: PubMed
    102. Tishler RB, Norris CM, Colevas AD, Lamb CC, Karp D, Busse PM, Nixon A, Frankenthaler R, Lake-Willcutt B, Costello R, Case M, Posner MR. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer. 2002 Oct 1; 95(7):1472-81.
      View in: PubMed
    103. Ringström E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res. 2002 Oct; 8(10):3187-92.
      View in: PubMed
    104. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene. 2002 Jun 20; 21(27):4231-6.
      View in: PubMed
    105. Posner MR. Head and neck cancer carcinoma: new directions for treatment. MedGenMed. 2002 Jun 7; 4(3):15.
      View in: PubMed
    106. Colevas AD, Norris CM, Tishler RB, Lamb CC, Fried MP, Goguen LA, Gopal HV, Costello R, Read R, Adak S, Posner MR. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol. 2002 Apr; 25(2):153-9.
      View in: PubMed
    107. Colevas AD, Read R, Thornhill J, Adak S, Tishler R, Busse P, Li Y, Posner M. Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2001 Nov 1; 51(3):599-604.
      View in: PubMed
    108. Colevas AD, Amrein PC, Gomolin H, Barton JJ, Read RR, Adak S, Benner S, Costello R, Posner MR. A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck. Cancer. 2001 Jul 15; 92(2):326-31.
      View in: PubMed
    109. Posner MR, Glisson B, Frenette G, Al-Sarraf M, Colevas AD, Norris CM, Seroskie JD, Shin DM, Olivares R, Garay CA. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2001 Feb 15; 19(4):1096-104.
      View in: PubMed
    110. Posner MR. Docetaxel in squamous cell cancer of the head and neck. Anticancer Drugs. 2001 Feb; 12 Suppl 1:S21-4.
      View in: PubMed
    111. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J, McCarty T, Landers S, Blackburn A, Romel L, Randlev B, Kaye S, Kirn D. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001 Jan 15; 19(2):289-98.
      View in: PubMed
    112. Posner MR, Colevas AD, Tishler RB. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Semin Oncol. 2000 Aug; 27(4 Suppl 8):13-24.
      View in: PubMed
    113. Colevas AD, Adak S, Amrein PC, Barton JJ, Costello R, Posner MR. A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck. Ann Oncol. 2000 May; 11(5):535-9.
      View in: PubMed
    114. Colevas AD, Norris CM, Tishler RB, Fried MP, Gomolin HI, Amrein P, Nixon A, Lamb C, Costello R, Barton J, Read R, Adak S, Posner MR. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol. 1999 Nov; 17(11):3503-11.
      View in: PubMed
    115. Posner MR, Cavacini LA, Upton MP, Tillman KC, Gornstein ER, Norris CM. Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. Clin Cancer Res. 1999 Aug; 5(8):2261-70.
      View in: PubMed
    116. Tishler RB, Busse PM, Norris CM, Rossi R, Poulin M, Thornhill L, Costello R, Peters ES, Colevas AD, Posner MR. An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. Int J Radiat Oncol Biol Phys. 1999 Mar 15; 43(5):1001-8.
      View in: PubMed
    117. Colevas AD, Posner MR. Docetaxel in head and neck cancer: a review. Am J Clin Oncol. 1998 Oct; 21(5):482-6.
      View in: PubMed
    118. Colevas AD, Busse PM, Norris CM, Fried M, Tishler RB, Poulin M, Fabian RL, Fitzgerald TJ, Dreyfuss A, Peters ES, Adak S, Costello R, Barton JJ, Posner MR. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol. 1998 Apr; 16(4):1331-9.
      View in: PubMed
    119. Clark JR, Busse PM, Norris CM, Andersen JW, Dreyfuss AI, Rossi RM, Poulin MD, Colevas AD, Tishler RB, Costello R, Lucarini JW, Lucarini D, Thornhill L, Lackey M, Peters E, Posner MR. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. J Clin Oncol. 1997 Sep; 15(9):3100-10.
      View in: PubMed
    120. Sanz-Altamira PM, Spence LD, Huberman MS, Posner MR, Steele G, Perry LJ, Stuart KE. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum. 1997 Jul; 40(7):770-5.
      View in: PubMed
    121. Posner MR, Colevas AD. Induction chemotherapy in the management of squamous cell cancer of the head and neck. Cancer J Sci Am. 1997 Mar-Apr; 3(2):73-5.
      View in: PubMed
    122. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R, Posner MR. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 1996 May; 14(5):1672-8.
      View in: PubMed
    123. Glicksman AS, Slotman G, Doolittle C, Clark J, Koness J, Coachman N, Posner M, DeRosa E, Wanebo H. Concurrent cis-platinum and radiation with or without surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1994 Dec 1; 30(5):1043-50.
      View in: PubMed
    124. Brennan MF, Pisters PW, Posner M, Quesada O, Shike M. A prospective randomized trial of total parenteral nutrition after major pancreatic resection for malignancy. Ann Surg. 1994 Oct; 220(4):436-41; discussion 441-4.
      View in: PubMed
    125. Montefiori DC, Graham BS, Zhou J, Zhou J, Bucco RA, Schwartz DH, Cavacini LA, Posner MR. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network. J Clin Invest. 1993 Aug; 92(2):840-7.
      View in: PubMed
    126. Browne MJ, Mayer KH, Chafee SB, Dudley MN, Posner MR, Steinberg SM, Graham KK, Geletko SM, Zinner SH, Denman SL, et al. 2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis. 1993 Jan; 167(1):21-9.
      View in: PubMed
    127. Posner MR, Darnowski JW, Weitberg AB, Dudley MN, Corvese D, Cummings FJ, Clark J, Murray C, Clendennin N, Bigley J, et al. High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial. Cancer. 1992 Dec 15; 70(12):2929-34.
      View in: PubMed
    128. Zelkowitz RS, Posner MR, Cummings F, Beitz J, Weitberg AB. A phase I/II trial of 5-fluorouracil and etoposide in metastatic colorectal carcinoma. Am J Clin Oncol. 1989 Dec; 12(6):491-3.
      View in: PubMed
    129. Forastiere AA, Belliveau JF, Goren MP, Vogel WC, Posner MR, O'Leary GP. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients. Cancer Res. 1988 Jul 1; 48(13):3869-74.
      View in: PubMed
    130. Ervin TJ, Clark JR, Weichselbaum RR, Fallon BG, Miller D, Fabian RL, Posner MR, Norris CM, Tuttle SA, Schoenfeld DA, et al. An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol. 1987 Jan; 5(1):10-20.
      View in: PubMed
    131. Hayes DF, Lechan RM, Posner MR, Weichselbaum RR, Miller D, Ervin TJ. The syndrome of inappropriate antidiuretic hormone secretion associated with induction chemotherapy for squamous cell carcinoma of the head and neck. J Surg Oncol. 1986 Jul; 32(3):150-2.
      View in: PubMed
    132. Posner MR, Skarin AT, Clark J, Ervin TJ. Phase I study of continuous-infusion cisplatin. Cancer Treat Rep. 1986 Jul; 70(7):847-50.
      View in: PubMed
    133. Posner MR, Weichselbaum RR, Fitzgerald TJ, Clark JR, Rose C, Fabian RL, Norris CM, Miller D, Tuttle SA, Ervin TJ. Treatment complications after sequential combination chemotherapy and radiotherapy with or without surgery in previously untreated squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1985 Nov; 11(11):1887-93.
      View in: PubMed
    134. Weichselbaum RR, Clark JR, Miller D, Posner MR, Ervin TJ. Combined modality treatment of head and neck cancer with cisplatin, bleomycin, methotrexate-leucovorin chemotherapy. Cancer. 1985 May 1; 55(9 Suppl):2149-55.
      View in: PubMed
    135. Ervin TJ, Weichselbaum RR, Fabian RL, Miller D, Norris CM, Posner MR, Rose C, Lockhart P, Tuttle SA, MacIntyre JM, et al. Advanced squamous carcinoma of the head and neck. A preliminary report of neoadjuvant chemotherapy with cisplatin, bleomycin, and methotrexate. Arch Otolaryngol. 1984 Apr; 110(4):241-5.
      View in: PubMed
    136. Posner MR, Ervin TJ, Miller D, Fabian RL, Norris CM, Weichselbaum RR, Rose C. Incidence of hypothyroidism following multimodality treatment for advanced squamous cell cancer of the head and neck. Laryngoscope. 1984 Apr; 94(4):451-54.
      View in: PubMed
    137. Ervin TJ, Weichselbaum RR, Miller D, Posner MR, Fabian RL, Rose C, Norris CM. The role of chemotherapy for advanced carcinoma of the supraglottic and glottic larynx. Otolaryngol Clin North Am. 1984 Feb; 17(1):209-14.
      View in: PubMed
    138. Posner MR, Ervin TJ, Weichselbaum RR, Fabian RL, Miller D. Chemotherapy of advanced salivary gland neoplasms. Cancer. 1982 Dec 1; 50(11):2261-4.
      View in: PubMed
    139. Weichselbaum RR, Posner MR, Ervin TJ, Fabian RL, Miller D. Toxicity of aggressive multimodality therapy including cisplatinum, bleomycin and methotrexate with radiation and/or surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1982 May; 8(5):909-13.
      View in: PubMed
    140. Ervin TJ, Karp DD, Weichselbaum RR, Posner MR, Fabian RL, Miller D. Role of chemotherapy in the multidisciplinary approach to advanced head and neck cancer: potentials and problems. Ann Otol Rhinol Laryngol. 1981 Sep-Oct; 90(5 Pt 1):506-11.
      View in: PubMed
    141. Ervin TJ, Weichselbaum R, Miller D, Meshad M, Posner M, Fabian R. Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin, and methotrexate (PBM). Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):787-91.
      View in: PubMed
    Posner's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067